Quality of Life After Axillary or Groin Sentinel Lymph Node Biopsy, With or Without Completion Lymph Node Dissection, in Patients With Cutaneous Melanoma

被引:84
|
作者
de Vries, Mattijs [1 ,2 ]
Hoekstra, Harald J. [1 ,2 ]
Hoekstra-Weebers, Josette E. H. M. [2 ,3 ,4 ,5 ]
机构
[1] Univ Med Ctr Groningen, Dept Surg Oncol, NL-9713 AV Groningen, Netherlands
[2] Univ Groningen, Groningen, Netherlands
[3] Univ Med Ctr Groningen, Wenckebach Inst, NL-9713 AV Groningen, Netherlands
[4] Comprehens Canc Ctr NE Netherlands, Groningen, Netherlands
[5] Univ Med Ctr Groningen, Grad Sch Hlth Res, SHARE, NL-9713 AV Groningen, Netherlands
关键词
BREAST-CANCER PATIENTS; EARLY-STAGE MELANOMA; LONG-TERM SURVIVORS; OPERATIVE MORBIDITY; LOWER-EXTREMITY; ONCOLOGY; HEALTH; TRIAL; POPULATION; DISABILITY;
D O I
10.1245/s10434-009-0602-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of this study was to asses quality of life (QoL) after axillary or inguinal sentinel lymph node biopsy (SLNB) with or without completion lymph node dissection (CLND) in patients with cutaneous melanoma by comparing patients to a norm group of the general population and by comparing QoL between four patient groups depending on surgical procedure and location, i.e., patients receiving an axillary or groin SLNB, or an axillary or groin CLND. Between 1995 and 2003, a total of 242 axillary and inguinal SLNBs were performed. Of the 127 patients eligible for the study, 116 patients participated (91%). QoL was measured by the 30-item European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), the McGill Pain Questionnaire and the Groningen Activity Restriction Scale. Median age at diagnosis was 50 (range, 18-77) years; median Breslow thickness 2.0 (range, 1-13) mm; median follow-up 56 (range, 4-94) months. SLNB only was performed in 89 patients (77%): 48 in the groin and 41 in the axilla. CLND was performed in 27 patients (23%): 13 in the axilla and 14 in the groin. More postoperative complications (13 vs. 5; P < 0.001) and lymphedema (10 vs. 8; P < 0.001) occurred in the CLND group than in the SLNB group. The total group of patients reported better physical (P < 0.001), role (P < 0.001), emotional (P < 0.001), and social functioning (P = 0.049), global QoL (P < 0.001), and less fatigue (P < 0.001) and pain (P < 0.001) than a German norm group. Analysis of variance revealed significant differences in role functioning (P = 0.02) and tendencies toward physical problems (P = 0.051) and fatigue (P = 0.051) between the four groups. Post hoc Bonferroni tests showed that the axillary CLND group had more problems than the axillary and inguinal SLNB groups. Kruskal-Wallis tests showed that the axillary CLND group reported most pain. QoL in melanoma survivors after axillary or inguinal SLNB with or without CLND was better than that in a norm group. Patients who underwent CLND in the axilla after SLNB reported most problems.
引用
收藏
页码:2840 / 2847
页数:8
相关论文
共 50 条
  • [1] Quality of Life After Axillary or Groin Sentinel Lymph Node Biopsy, With or Without Completion Lymph Node Dissection, in Patients With Cutaneous Melanoma
    Mattijs de Vries
    Harald J. Hoekstra
    Josette E. H. M. Hoekstra-Weebers
    [J]. Annals of Surgical Oncology, 2009, 16 : 2840 - 2847
  • [2] Morbidity after inguinal sentinel lymph node biopsy and completion lymph node dissection in patients with cutaneous melanoma
    de Vries, M.
    Vonkeman, W. G.
    van Ginkel, R. J.
    Hoekstra, H. J.
    [J]. EJSO, 2006, 32 (07): : 785 - 789
  • [3] Sentinel Lymph Node Biopsy and Completion Lymph Node Dissection for Melanoma
    Sabran J. Masoud
    Jennifer A. Perone
    Norma E. Farrow
    Paul J. Mosca
    Douglas S. Tyler
    Georgia M. Beasley
    [J]. Current Treatment Options in Oncology, 2018, 19
  • [4] Sentinel Lymph Node Biopsy and Completion Lymph Node Dissection for Melanoma
    Masoud, Sabran J.
    Perone, Jennifer A.
    Farrow, Norma E.
    Mosca, Paul J.
    Tyler, Douglas S.
    Beasley, Georgia M.
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2018, 19 (11)
  • [5] Sentinel Lymph Node Biopsy and Completion Lymph Node Dissection in Melanoma
    Ross, Merrick I.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (06) : 368 - 371
  • [6] Completion lymph node dissection in patients with melanoma and positive sentinel lymph node biopsy
    Link, Jacqueline
    [J]. JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2017, 30 (07): : 31 - 34
  • [7] Correction to: Sentinel Lymph Node Biopsy and Completion Lymph Node Dissection for Melanoma
    Sabran J. Masoud
    Jennifer A. Perone
    Norma E. Farrow
    Paul J. Mosca
    Douglas S. Tyler
    Georgia M. Beasley
    [J]. Current Treatment Options in Oncology, 2019, 20
  • [8] Quality of life after sentinel lymph node biopsy in patients with cutaneous melanoma
    De Vries, M.
    Hoekstra-Weebers, J. E.
    Van Ginkel, R. J.
    Rietman, J. S.
    Hoekstra, H. J.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (02) : 112 - 112
  • [9] Necessity of Completion Pelvic Lymph Node Dissection after Positive Inguinal Sentinel Lymph Node Biopsy in Cutaneous Melanoma
    Carpenter, K.
    Forster, M. R.
    Sarantou, T.
    Salo, J. C.
    Hill, J. S.
    White, R. L., Jr.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2014, 21 : S111 - S111
  • [10] Morbidity and recurrence after completion lymph node dissection following sentinel lymph node biopsy in cutaneous malignant melanoma
    Guggenheim, Merlin M.
    Hug, Urs
    Jung, Florian J.
    Rousson, Valentin
    Aust, Matthias C.
    Calcagni, Maurizio
    Kuenzi, Walter
    Giovanoli, Pietro
    [J]. ANNALS OF SURGERY, 2008, 247 (04) : 687 - 693